New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
10:06 EDTHYGS, AVGO, MNDL, MCO, VRX, BBG, SYRG, ISSI, CFX, ARP, ORCL, EPE, CRZO, ATLS, MHFI, CXPOn The Fly: Analyst Initiation Summary
Atlas Energy (ATLS) initiated with a Buy at Deutsche Bank... Atlas Resource Partners (ARP) initiated with a Hold at Deutsche Bank... Bill Barrett (BBG) initiated with a Neutral at Mizuho... Carrizo Oil & Gas (CRZO) initiated with a Buy at Mizuho... Colfax (CFX) initiated with a Neutral at Longbow... Columbia Property Trust (CXP) initiated with a Market Perform at JMP Securities... EP Energy (EPE) initiated with a Neutral at Mizuho... Integrated Silicon (ISSI) initiated with a Buy at B. Riley... McGraw Hill Financial (MHFI) initiated with a Buy at Janney Capital... Oracle (ORCL) initiated with a Buy at Cantor... Synergy Resources (SYRG) initiated with an Outperform at Imperial Capital... Valeant (VRX) initiated with a Buy at Cantor... Mandalay Digital (MNDL) initiated with a Buy at Craig-Hallum... Hydrogenics (HYGS) initiated with a Buy at Ascendiant... Moody's (MCO) initiated with a Neutral at Janney Capital... Avago (AVGO) initiated with an Outperform at Pacific Crest.
News For ATLS;ARP;BBG;CRZO;CFX;CXP;EPE;ISSI;MHFI;ORCL;SYRG;VRX;MNDL;HYGS;MCO;AVGO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
February 23, 2015
12:53 EDTVRXAnalysts debate potential for competing Salix takeover bid
Subscribe for More Information
12:21 EDTVRXOn The Fly: Midday Wrap
Subscribe for More Information
10:22 EDTISSIIntegrated Silicon management to meet with Sidoti
Meetings to be held in Minneapolis on February 24 and in Chicago on February 25 hosted by Sidoti.
08:35 EDTARP, ATLSAtlas Energy subsidiary sees annualized cash distribution to be 70c-80c per unit
Atlas Energy Group, a wholly-owned subsidiary of Atlas Energy, announced that it currently expects annualized cash distributions to be 70c to 80c per common limited partner unit based on initial expectations of cash flow to its business. The current forecast includes, among other items, approximately $37.5M of cash distributions expected to be received from Atlas Resource Partners (ARP) from AEG's ownership of ARP's general partner and approximately 24.7M ARP limited partner units, and is based on ARP's current annualized distribution of $1.30 per unit.
08:29 EDTAVGOAvago shares should be bought ahead of earnings, says Pacific Crest
Subscribe for More Information
07:55 EDTVRXJefferies says other bidders may emerge for Salix
Jefferies says it could envision other bidders emerging for Salix (SLXP) and points out recent media reports have suggested Shire (SHPG) and Endo (ENDP) have considered making a bid for the company. It lists AstraZeneca (AZN) and Takeda as others who could have possible interest in Salix. The firm believes Valeant (VRX) could afford to pay more for Salix should other bidders emerge.
07:41 EDTVRXValeant buyout of Salix another smart deal, says UBS
Subscribe for More Information
07:13 EDTVRXSalix downgraded to Market Perform from Outperform at Leerink
Subscribe for More Information
07:03 EDTVRXValeant price target raised to $214 from $184 at Cantor
Subscribe for More Information
06:37 EDTVRXSalix downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray downgraded Salix Pharmaceuticals (SLXP) to Neutral saying that while it could "easily see" another bidder emerge, it does not expect any potential competing bids to be significantly higher than the Valeant (VRX) offer. Piper lowered its price target for Salix shares to $158 from $160.
06:05 EDTVRXValeant to host conference call
Subscribe for More Information
February 22, 2015
16:25 EDTVRXValeant says Dendreon acquisition expected to close Feb. 23, 2015
16:21 EDTVRXValeant expect Q1 cash EPS of at least $2.30 per share
Subscribe for More Information
16:18 EDTVRXValeant reports Q4 EPS $2.58 vs. $2.15 in Q413
Subscribe for More Information
16:07 EDTVRXValeant confirms acquiring Salix for $158 per share
Valeant Pharmaceuticals International (VRX) and Salix Pharmaceuticals (SLXP) announced that they have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Salix for $158 per share in cash, or a total enterprise value of approximately $14.5B. The transaction was approved by the Boards of Directors of both companies. Salix Pharmaceuticals is a widely recognized gastrointestinal market leader with a portfolio of 22 total products, including well-known prescription brands Xifaxan, Uceris, Relistor, and Apriso, as well as a strong near- term pipeline of innovative, new assets. "Salix's market-leading gastrointestinal franchise is an ideal strategic fit for Valeant's diversified portfolio of specialty products," said J. Michael Pearson, Valeant's chairman and CEO. "The growing GI market has attractive fundamentals, and Salix has a portfolio of terrific products that are outpacing the market in terms of volume growth and a promising near-term pipeline of innovative products. With strong brand recognition among specialist GI prescribers, a highly rated specialty sales force, and a significant product and commercial presence across the undertreated and underserved gastrointestinal market, this acquisition offers a compelling opportunity for Valeant to create a strong platform for growth and business development." The combination is expected to yield greater than $500M in annual cost savings from the cost base of the combined company. Synergies are expected to be achieved within six months of close, primarily from reductions in corporate overhead and R&D rationalization, with the cost to achieve these synergies to be approximately 65%. Valeant and Salix will determine how best to integrate the two companies to leverage the combined strengths of both while ensuring a smooth and orderly transition. Consistent with Valeant's approach to integrating Bausch + Lomb, there are no planned reductions to Salix's highly rated specialty sales forces or hospital, key account and field reimbursement teams and we will determine the optimal size of Primary Care Sales Force through the integration process.The acquisition is structured as an all-cash tender offer for all of the outstanding shares of Salix common stock at a price of $158 per share followed by a merger in which each remaining untendered share of Salix common stock would be converted into the right to receive the same $158 cash per share consideration as in the tender offer. The all-cash offer will be financed through a combination of bank debt and bonds. As a result of the need to draw down inventories, EBITDA will be artificially low in 2014 and 2015, resulting in the initial net leverage ratio of approximately 5.6. Valeant is committed to reducing its net leverage ratio to be below 4.0 by the second half of 2016. As a result of the plan to reduce wholesaler inventory levels in 2015, the transaction is expected to be modestly accretive to 2015 cash EPS, but over 20% accretive to 2016 cash EPS. Valeant does not expect any change to its credit ratings as a result of the transaction. The transaction, which is expected to close in the second quarter of 2015, is subject to customary closing conditions and regulatory approval.
15:59 EDTVRXValeant to buy Salix for $10.1B, FT says
Subscribe for More Information
February 20, 2015
11:46 EDTATLSTarga Resources shareholders approve share issuance in merger with Atlas Energy
Targa Resources (TRGP) announced that the stockholders of the company approved at a special meeting of stockholders held today the issuance of shares of common stock of the company in connection with the company's proposed merger with Atlas Energy, L.P. (ATLS). Approximately 76.15% of the shares of the company's common stock that were outstanding as of the record date of January 22 approved the share issuance, and approximately 91.50% of the shares of the company's common stock that were voted approved the share issuance. A special meeting of ATLS unitholders was also held to approve the merger agreement in connection with the ATLS Merger. Approximately 52.83% of the common units of ATLS that were outstanding as of the record date of January 22, 2015 approved the merger agreement in connection with the ATLS Merger, and approximately 99.28% of the common units of ATLS that were voted approved the ATLS Merger Agreement. A special meeting of unitholders of Atlas Pipeline Partners, L.P. (APL) was also held to approve the merger agreement in connection with Targa Resources Partners LP's (NGLS) proposed merger with APL. Approximately 54.84% of the common units of APL that were outstanding as of the record date of January 22 approved the merger agreement in connection with the APL Merger, and approximately 98.21% of the common units of APL that were voted approved the APL Merger Agreement. The approvals by the shareholders of the Company and the unitholders of ATLS and APL described above satisfy three of the conditions required to finalize the Atlas Mergers. The consummation of the Atlas Mergers is still subject to certain other conditions, including the previously announced spin-off by ATLS of its non-midstream assets. Each of the Transactions is contingent on one another, and the Transactions are expected to close concurrently on February 27.
11:38 EDTATLSAtlas Energy, Atlas Pipeline approve mergers with Targa, Targa Partners
Subscribe for More Information
09:45 EDTVRXValeant near deal to acquire Salix, CNBC's Faber reports
Subscribe for More Information
09:43 EDTVRXValeant nearing deal to acquire Salix, CNBC's Faber reports
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use